ChartMill assigns a Buy % Consensus number of 78% to BIOA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-08 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-22 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-03-24 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-28 | William Blair | Initiate | Market Perform |
| 2024-12-09 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-12-09 | Jefferies | Downgrade | Buy -> Hold |
| 2024-10-21 | Morgan Stanley | Initiate | Overweight |
| 2024-10-21 | Citigroup | Initiate | Buy |
| 2024-10-21 | Jefferies | Initiate | Buy |
10 analysts have analysed BIOA and the average price target is 12.24 USD. This implies a price decrease of -39.29% is expected in the next year compared to the current price of 20.16.
The consensus rating for BIOAGE LABS INC (BIOA) is 78 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering BIOAGE LABS INC (BIOA) is 10.